YB 200
Alternative Names: YB-200Latest Information Update: 09 Mar 2023
At a glance
- Originator LeukoCom
- Developer Ymmunobio
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD66 antigen inhibitors; CEACAM5 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malignant melanoma; Solid tumours